Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 495Neoplasms 301Breast Neoplasms 298Colorectal Neoplasms 229Neoplasm Metastasis 194Prostatic Neoplasms 174Ovarian Neoplasms 173Multiple Myeloma 158Lung Neoplasms 157Recurrence 134Melanoma 121Pancreatic Neoplasms 116Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 101Leukemia, Myeloid, Acute 101Endometrial Neoplasms 101Small Cell Lung Carcinoma 88Leukemia, Lymphocytic, Chronic, B-Cell 86Triple Negative Breast Neoplasms 85Lymphoma, Non-Hodgkin 85Carcinoma, Renal Cell 82Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 67Advanced Solid Tumors 66Parkinson Disease 4, Autosomal Dominant Lewy Body 62Lymphoma 61Glioblastoma 58Head and Neck Neoplasms 56

Interventions

durvalumab 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Locally Advanced or Metastatic Solid Tumours × 90 days × Clear all
NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

AstraZeneca

Phase 2 Active not recruiting
126 enrolled 30 charts
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡